PACIFIC NORTHWEST NODE

PACIFIC NORTHWEST NODE

Principal Investigators:
Dennis Donovan, PhD [email]
Alcohol and Drug Abuse Institute
University of Washington
1107 NE 45th St., Suite 120
Seattle, WA 98105-4631

John Roll, PhD [email]
Washington State University
Program for Excellence in Addictions
PO Box 1495
Spokane, WA 99210-1495

Find Node Publications
PN Node News blog

Node web site
NIDA web site

The Pacific Northwest Node (formerly the "Washington Node") joined the CTN in January 2001, and includes Washington and Alaska, with dissemination partners in Nevada and Oregon. Its CTPs provide a mix of settings including: urban and rural, private and public sector, in-patient/residential and outpatient, and drug free and methadone maintenance programs. The CTPs provide a wide range of treatment services to nearly 12,000 clients per year. All available services are also targeted to specific groups having special needs such as women, the elderly, Native Americans and Alaska Natives, dual disorder clients, homeless populations, and adolescent clients.

In 2010, the Pacific Northwest Node added several Dissemination Partners:

Research Utilization Contacts: Elizabeth Wells, PhD [email]; Janet Katz, PhD [email]


PACIFIC NORTHWEST NODE PROTOCOL INVOLVEMENT

CTN-0003 Suboxone (Buprenorphine/Naloxone) Taper: A Comparison of Taper Schedules
CTN-0008 Assessment of the National Drug Abuse Clinical Trials Network: A Baseline for Investigating the Diffusion of Innovation
CTN-0012 Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
CTN-0015 Women's Treatment for Trauma and Substance Use Disorders
CTN-0017 HIV and HCV Intervention in Drug Treatment Settings
CTN-0018 Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment
CTN-0019 Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment
CTN-0027 Starting Treatment with Agonist Replacement Therapies (START)
CTN-0027-A-1 START Pharmacogenetics: Exploratory Genetic Studies in Starting Treatment with Agonist Replacement Therapies
CTN-0027-A-2 Retention of Suboxone Patients in START: Perspectives of Providers and Patients
CTN-0030 Prescription Opiate Abuse Treatment Study (POATS)
CTN-0030-A-1 Collection of Economic Data for the Prescription Opioid Addiction Treatment Study
CTN-0031 Stimulant Abuser Groups to Engage in 12-Step (STAGE-12): Evaluation of a Combined Individual-Group Intervention to Reduce Stimulant and Other Drug Use by Increasing 12-Step Involvement
CTN-0031-A-1 An Evaluation of Neurocognitive Function, Oxidative Damage, and Their Association with Treatment Outcomes in Methamphetamine and Cocaine Abusers
CTN-0031-A-2 The Role of Alcohol Consumption Classifications of Alcohol Use Disorders: A Clinical Study
CTN-0033-Ot-3 Methamphetamine: Where Does It Fit in the Bigger Picture of Drug Use of American Indian and Alaska Native Communities and Treatment Seekers?
CTN-0034-Ot Developing Research Capacity and Culturally Appropriate Research Methods: Community-Based Participatory Research Manual for Collaborative Research in Drug Abuse for American Indians and Alaska Natives
CTN-0040-S Pattern of Alcohol Use and Alcohol-Related Diagnoses among Drug Abusing/Dependent Participants
CTN-0044 Web-Delivery of Evidence-Based, Psychosocial Treatment for Substance Use Disorders
CTN-0047 Screening Motivational Assessment and Referral to Treatment in Emergency Departments (SMART-ED): Evaluation of Screening, Brief Intervention, Referral to Treatment (SBIRT) and Booster Session for Drug Use Patients Presenting for Treatment in the Emergency Department
CTN-0048 Cocaine Use Reduction with Buprenorphine (CURB)
CTN-0050 Long Term Follow-Up of START Patients
CTN-0051 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)
CTN-0051-A-1 Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT) Genetics Study
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 10/2011 -- http://ctndisseminationlibrary.org/nodes/pnnode.htm
info@ctndisseminationlibrary.org